Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 116

1.

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.

Gantner P, Bani-Sadr F, Garraffo R, Roger PM, Treger M, Jovelin T, Pugliese P, Rey D; Dat’AIDS cohort..

PLoS One. 2016 Oct 31;11(10):e0164240. doi: 10.1371/journal.pone.0164240. eCollection 2016 Oct 31.

2.

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.

de Boissieu P, Dramé M, Raffi F, Cabie A, Poizot-Martin I, Cotte L, Garraffo R, Delobel P, Huleux T, Rey D, Bani-Sadr F; Dat’AIDS Study Group..

Medicine (Baltimore). 2016 Sep;95(37):e4890. doi: 10.1097/MD.0000000000004890.

3.

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course.

Raffi F, Le Moing V, Assuied A, Habak S, Spire B, Cazanave C, Billaud E, Dellamonica P, Ferry T, Fagard C, Leport C; and the ANRS CO8 COPILOTE Study Group..

J Antimicrob Chemother. 2017 Jan;72(1):240-245. Epub 2016 Sep 13.

PMID:
27629069
4.

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).

Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC., Group BS.

Antivir Ther. 2016 Sep 1. doi: 10.3851/IMP3074. [Epub ahead of print]

PMID:
27583701
5.

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.

Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups..

AIDS. 2016 Aug 24;30(13):2085-90. doi: 10.1097/QAD.0000000000001143.

PMID:
27149089
6.

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.

Flandre P, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Cuzin L; Dat'AIDS Study group..

HIV Med. 2016 May;17(5):380-4. doi: 10.1111/hiv.12306. Epub 2015 Aug 26.

PMID:
27093565
7.

Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.

Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM; ANRS HC27 BOCEPREVIH Study Group..

HIV Clin Trials. 2016 Mar;17(2):63-71. doi: 10.1080/15284336.2015.1135553. Epub 2016 Feb 11.

PMID:
27077673
8.

Impact of Age-related Comorbidities on Five-year Overall Mortality among Elderly HIV-Infected Patients in the Late HAART Era--Role of Chronic Renal Disease.

Hentzien M, Dramé M, Allavena C, Jacomet C, Valantin MA, Cabié A, Cuzin L, Rey D, Pugliese P, Bani-Sadr F; Dat'AIDS Study Group..

J Nutr Health Aging. 2016 Apr;20(4):408-14. doi: 10.1007/s12603-015-0608-7.

PMID:
26999241
9.

Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients.

Allavena C, Katlama C, Cotte L, Roger PM, Delobel P, Cheret A, Duvivier C, Poizot-Martin I, Hoen B, Cabie A, Cheret A, Lahoulou R, Raffi F, Pugliese P; Dat’AIDS Study group..

Infect Dis (Lond). 2016;48(5):392-8. doi: 10.3109/23744235.2015.1133927. Epub 2016 Jan 13.

PMID:
26757613
10.

Potential for Drug-Drug Interactions between Antiretrovirals and HCV Direct Acting Antivirals in a Large Cohort of HIV/HCV Coinfected Patients.

Poizot-Martin I, Naqvi A, Obry-Roguet V, Valantin MA, Cuzin L, Billaud E, Cheret A, Rey D, Jacomet C, Duvivier C, Pugliese P, Pradat P, Cotte L; Hepadat'AIDS Study Group..

PLoS One. 2015 Oct 21;10(10):e0141164. doi: 10.1371/journal.pone.0141164. eCollection 2015 Oct 21.

11.

Update on a proper use of systemic fluoroquinolones in adult patients (ciprofloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin. SPILF.).

Chidiac C; SPILF working group..

Med Mal Infect. 2015 Sep;45(9):348-73. doi: 10.1016/j.medmal.2015.07.003. Epub 2015 Oct 1. No abstract available.

PMID:
26432627
12.

Comparative Effectiveness of First Antiretroviral Regimens in Clinical Practice Using a Causal Approach.

Cuzin L, Pugliese P, Allavena C, Katlama C, Cotte L, Cheret A, Cabié A, Rey D, Chirouze C, Bani-Sadr F, Flandre P; Dat'AIDS Study group..

Medicine (Baltimore). 2015 Sep;94(39):e1668. doi: 10.1097/MD.0000000000001668.

13.

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy.

Cuzin L, Pugliese P, Sauné K, Allavena C, Ghosn J, Cottalorda J, Rodallec A, Chaix ML, Fafi-Kremer S, Soulié C, Ouka M, Charpentier C, Bocket L, Mirand A, Guiguet M; Dat’AIDS study group..

AIDS. 2015 Aug 24;29(13):1665-71. doi: 10.1097/QAD.0000000000000723.

PMID:
26372277
14.

Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort.

Protopopescu C, Raffi F, Spire B, Hardel L, Michelet C, Cheneau C, Le Moing V, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group..

Antivir Ther. 2015;20(7):763-72. doi: 10.3851/IMP2960. Epub 2015 Apr 10.

PMID:
25859625
15.

Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity.

Bastard JP, Fellahi S, Couffignal C, Raffi F, Gras G, Hardel L, Sobel A, Leport C, Fardet L, Capeau J; ANRS CO8 APROCO-COPILOTE Cohort Study Group..

J Antimicrob Chemother. 2015;70(6):1816-24. doi: 10.1093/jac/dkv036. Epub 2015 Mar 1.

PMID:
25733587
16.

Successful antiretroviral therapy by using unusual antiretroviral combinations in heavily pre-treated patients: two case reports.

Taramasso L, Dentone C, Alessandrini A, Bruzzone B, Icardi G, Garraffo R, De Macina I, Viscoli C, Di Biagio A; HIV/HCV Collaborative Liguria Group..

Int J STD AIDS. 2015 Oct;26(11):831-4. doi: 10.1177/0956462414556330. Epub 2014 Oct 20.

PMID:
25332227
17.

From antiretroviral originator to generic drugs: bioequivalence and pharmacovigilance.

Bagheri H, Garraffo R, Dellamonica P.

Med Mal Infect. 2014 Oct;44(10):464-9. doi: 10.1016/j.medmal.2014.08.003. Epub 2014 Sep 16.

PMID:
25234382
18.

Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.

Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Miailhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, Taburet AM, Teicher E; Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group..

Clin Infect Dis. 2014 Oct 15;59(8):1177-84. doi: 10.1093/cid/ciu515. Epub 2014 Jul 3.

PMID:
24992955
19.

Can the "seek, test, treat, and retain" strategy be effective in France?

Cuzin L, Allavena C, Pugliese P, Rey D, Hoen B, Poizot-Martin I, Cabie A, Yazdanpanah Y; DATʼAIDS Study Group..

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):e119-21. doi: 10.1097/QAI.0b013e3182809f08. No abstract available.

PMID:
23933718
20.

Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription.

Colombie V, Pugliese-Wehrlen S, Deuffic-Burban S, Cuzin L, Pugliese P, Katlama C, Poizot-Martin I, Raffi F, Cabie A, Dellamonica P, Yazdanpanah Y; Dat'Aids..

Int J STD AIDS. 2012 Dec;23(12):865-9. doi: 10.1258/ijsa.2012.011438.

PMID:
23258826

Supplemental Content

Loading ...
Support Center